Key Drivers
- High ROE/ROIC
- Heavy leverage
- Modest liquidity
AIAI Summary
CON shows real cash-generating, margin-improving operational momentum but its equity upside is now materially contingent on balance-sheet execution—specifically successful deleveraging/refinancing and accretive integration of acquisitions—so investors should monitor debt maturities, interest expense trajectory, covenant headroom, and early margin evidence from recent M&A as the primary determinants of upside versus rapid downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High ROE/ROIC
- •Heavy leverage
- •Modest liquidity
CON delivers high reported returns and strong free cash flow supporting a modest dividend, but heavy leverage, limited liquidity and large intangibles materially raise solvency and asset-quality risk.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Oversold momentum
- •Clear support band
CON is in a short-term downtrend trading below its last-month SMA (~$22.91) with oversold RSI (~26) suggesting mean-reversion upside into support around $21.60–$21.70 while resistance sits near $22.91 and the $23.60–$23.90 band.
~8% drop from late‑February highs (~$23.89) into the $21.4–$21.7 area
Sentiment & News
Key News Insights:
- •Revenue beat
- •EPS outperformance
- •Analyst support
Concentra topped expectations with Q4 2025 revenue rising 15.9% to $539.1M and adjusted EPS $0.28 vs $0.23 consensus, triggering analyst "Moderate Buy" support and peer-comparison interest.
Stronger results and analyst backing should underpin near-term share momentum and potential valuation re-rating versus peers
Similar Companies in Healthcare
Other companies in the same sector with AI ratings